

#54127

Date: February 14, 2024

Subject: Adjusted GT Biopharma, Inc. - Cash In Lieu Settlement

Adjusted Option Symbol: GTBP1

Adjusted GT Biopharma, Inc. options were adjusted on February 5, 2024 (See OCC Information Memo #54050). The new deliverable became 1) 3 GT Biopharma, Inc. (GTBP) Common Shares and 2) Cash in lieu of approximately 0.3333 fractional GTBP Shares. Only settlement of the cash portion of GTBP1 options exercise/assignment activity was subject to delayed settlement.

OCC has been informed that a price of \$4.98 per whole GTBP share will be used to determine the cash in lieu amount at a rate of 0.3333. Accordingly, the cash in lieu amount is:

 $0.3333 \times 4.98 = 1.66 \text{ per GTBP1 Contract}$

Now that the exact cash in lieu amount has been determined, OCC will require Put exercisers and Call assignees, during the period of February 5, 2024 through February 14, 2024, to deliver the appropriate cash amount

The cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.

Terms of the GTBP1 options are as follows:

New Deliverable

Per Contract: 1) 3 GT Biopharma, Inc. (GTBP) Common Shares

2) \$1.66 Cash

Strike Prices: Unchanged

CUSIP: GTBP: 36254L308

Multiplier: 100 (i.e., a premium of 1.50 yields \$150)

Settlement

The GTBP component of GTBP1 exercise/assignment activity from February 5, 2024 through February 13, 2024, has settled through National Security Clearing Corporation (NSCC). The \$1.66 cash amount will be settled by OCC.

Pricing

The underlying price for GTBP1 will be determined as follows:

$$GTBP1 = 0.03 (GTBP) + 0.0166$$

For example, if GTBP closes at 3.77, the GTBP1 price would be calculated as follows:

$$GTBP1 = 0.03(3.77) + 0.0166 = 0.13$$

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.